共 6 条
[1]
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone[J] Brent A. Neuschwander-Tetri;Elizabeth M. Brunt;Kent R. Wehmeier;Dana Oliver;Bruce R. Bacon Hepatology 2003,
[2]
Nonalcoholic fatty liver; steatohepatitis; and the metabolic syndrome[J] Giulio Marchesini;Elisabetta Bugianesi;Gabriele Forlani;Fernanda Cerrelli;Marco Lenzi;Rita Manini;Stefania Natale;Ester Vanni;Nicola Villanova;Nazario Melchionda;Mario Rizzetto Hepatology 2003,
[3]
Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background[J] Sei-ichiro Kojima;Norihito Watanabe;Makoto Numata;Tetsuhei Ogawa;Shohei Matsuzaki Journal of Gastroenterology 2003,
[4]
Nash-related liver failure: one hit too many?[J] Christopher P Day The American Journal of Gastroenterology 2002,
[5]
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver[J] Takato Ueno;Hiroshi Sugawara;Koodo Sujaku;Osamu Hashimoto;Riko Tsuji;Seishu Tamaki;Takuji Torimura;Sadataka Inuzuka;Michio Sata;Kyuichi Tanikawa Journal of Hepatology 1997,
[6]
Liver Histology in a ‘Normal’ Population—Examinations of 503 Consecutive Fatal Traffic Casualties[J] M. Hilden;P. Christoffersen;E. Juhl;J. B. Dalgaard Scandinavian Journal of Gastroenterology 1977,

